GLP-2 (LY3298176) – 30 Capsules
$349.99
GLP-2 is a dual GIP and GLP-1 receptor agonist selected by customers focused on appetite control, glucose metabolism and advanced body-weight support. This capsule format is offered with a stated strength of 4 mg active; 300 mg SNAC; 30 capsules.
Description
Description
GLP-2 is a dual GIP and GLP-1 receptor agonist selected by customers focused on appetite control, glucose metabolism and advanced body-weight support. This capsule format is offered with a stated strength of 4 mg active; 300 mg SNAC; 30 capsules.
Customers receive a clearly identified GLP-2 (LY3298176) (inferred), SNAC product with third-party testing, lot-specific documentation and straightforward storage information. Formula, molecular weight, mechanism and finished-product details are organized below for easy comparison.
Potential Benefits and Product Highlights
- Supports appetite regulation and satiety.
- Promotes glucose-dependent insulin signaling through two incretin pathways.
- Human trials of approved formulations show meaningful weight and glycemic benefits.
- Dual-receptor activity offers a different metabolic profile from GLP-1-only products.
- Independent third-party testing with lot-specific quality documentation.
Product Details
| Product name | GLP-2 (LY3298176) + SNAC – 4 mg / 300 mg, 30 Capsules |
|---|---|
| Main category | Weight Management & Metabolic |
| Subcategory | Weight Management Capsules |
| Product format | Capsules |
| Declared strength | 4 mg active; 300 mg SNAC; 30 capsules |
| Active identity / composition | GLP-2 (LY3298176) (inferred), SNAC |
| Quality documentation | Independent third-party testing and lot-specific Certificate of Analysis |
Chemical Information
| Component 1 | GLP-2 (LY3298176) |
|---|---|
| GLP-2 (LY3298176) formula / mass | C₂₂₅H₃₄₈N₄₈O₆₈; approximately 4,813.5 g/mol |
| Peptide length | 39 amino-acid residues with noncanonical modifications |
| Peptide architecture | Linear peptide conjugated to a C20 fatty diacid through a linker |
| Target class | Dual GIP and GLP-1 receptor agonist |
| Component 2 | Salcaprozate sodium (SNAC) |
| SNAC formula / mass | C₁₅H₂₀NNaO₄; approximately 301.31 g/mol |
| SNAC structure class | Sodium salt of an acylated amino-acid-derived absorption enhancer |
| Product type | Physical two-component capsule formulation; no single molecular formula |
| Presentation | 4 mg / 300 mg; 30 capsules |
How It Works
GLP-2 (LY3298176) activates both GIP and GLP-1 receptors. This dual action affects appetite, insulin release, nutrient handling and metabolic signaling after meals.
Evidence note: Substantial human evidence exists for approved GLP-2 (LY3298176) products, but results, tolerability and appropriate use require individualized professional guidance.
Product Strength and Usage Information
This capsule format is offered with a stated strength of 4 mg active; 300 mg SNAC; 30 capsules. Check the current label, serving or unit information and lot-specific documentation before use.
No single dosage suits every compound, goal or customer. Use should follow the product label and appropriate professional guidance, especially for potent hormones, prescription-class ingredients and investigational compounds.
Quality and Testing
Identity, purity and finished-product content are reviewed as separate quality attributes. The lot-specific Certificate of Analysis should identify the methods, results, batch number, testing provider and test date.
- Chromatographic testing evaluates purity and related substances.
- Mass spectrometry supports molecular identity and expected mass.
- Finished-product testing evaluates the supplied concentration, unit content, fill, count, uniformity or physical presentation as applicable.
- Lot-specific documentation supports confident purchasing and product traceability.
Storage and Handling
- Store in a cool, dry place away from direct sunlight.
- Keep the container tightly closed and protect the contents from humidity.
- Retain the original label, lot number and Certificate of Analysis.
Frequently Asked Questions
What is included in this product?
GLP-2 (LY3298176) + SNAC – 4 mg / 300 mg, 30 Capsules supplied in a capsule format with the declared composition and strength shown in the specifications.
What potential benefits are associated with it?
Potential areas of interest include supports appetite regulation and satiety, promotes glucose-dependent insulin signaling through two incretin pathways, human trials of approved formulations show meaningful weight and glycemic benefits.
How does it work?
GLP-2 (LY3298176) activates both GIP and GLP-1 receptors. This dual action affects appetite, insulin release, nutrient handling and metabolic signaling after meals.
How strong is the evidence?
Substantial human evidence exists for approved GLP-2 (LY3298176) products, but results, tolerability and appropriate use require individualized professional guidance.
How is product quality documented?
Independent third-party testing and a lot-specific Certificate of Analysis provide identity, purity and finished-product information.
How should the product be stored?
Keep the product in its original container and follow the temperature, light and handling conditions shown on the label.
What should be checked when the product arrives?
Review the product name, format, strength, lot number, container integrity and matching Certificate of Analysis.
Related products
Tesamorelin (5mg, 10mg)
MOTS-c – 10mg
Sermorelin 10mg Multi-Use Vial
GHRP-2 (5mg)
CJC with DAC (2mg)
Ipamorelin (5mg)
